. 2011 Jun 16;6(6):e20740. doi: 10.1371/journal.pone.0020740

Table 3. Overview of the quantity and quality of final UCB-NK products generated from enriched CD34⁺ cells using static bags and single use bioreactors.

	Donor	CD34⁺ cells (x10⁶)	fold expansion	CD56⁺ cells (%)	CD56⁺ cells (x10⁹)
static bag	7	1.7	1,770	63	1.9
	8	1.4	759	80	0.9
	9	1.3	1,291	70	1.2
bioreactor	10	0.9	2,549	95	2.2
	13	1.5	1,764	90	2.4
	15	1.5	2,657	92	3.7
	16	1.2	1,435	92	1.6

The table summarizes the generation of UCB-NK cell therapy products generated in static bags (Donor 7, 8 and 9) or bioreactors cultures (Donor 10, 13, 15 and 16).

Table 3. Overview of the quantity and quality of final UCB-NK products generated from enriched CD34+ cells using static bags and single use bioreactors.

Table 3. Overview of the quantity and quality of final UCB-NK products generated from enriched CD34⁺ cells using static bags and single use bioreactors.